Director Quimi Daphne purchases 5,000 shares of IPSC at $1.53 as stock trades -70.1% from 52-week high
Quimi Daphne, a Director, purchased 5,000 shares at $1.53 on 2024-09-12, establishing an initial position in Century Therapeutics. The company is unprofitable with net income of $-31.2M in its most recent full year, while annual revenue growth contracted by -57.0%, reflecting significant operational challenges. The stock is currently priced at $1.59, down -70.1% from its 52-week high of $5.32, suggesting a distressed valuation environment. Across Quimi Daphne's cross-ticker trading history, prior purchases have averaged +5.2% returns over 90 days with a 100% win rate, though this specific purchase at depressed levels and the company's deteriorating financial trajectory represent distinct risk factors to monitor independently of prior outcomes.